270 related articles for article (PubMed ID: 33600217)
21. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
[TBL] [Abstract][Full Text] [Related]
22. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
[TBL] [Abstract][Full Text] [Related]
23. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Blader JC; Pliszka SR; Kafantaris V; Foley CA; Crowell JA; Carlson GA; Sauder CL; Margulies DM; Sinha C; Sverd J; Matthews TL; Bailey BY; Daviss WB
J Am Acad Child Adolesc Psychiatry; 2013 Dec; 52(12):1281-93. PubMed ID: 24290461
[TBL] [Abstract][Full Text] [Related]
24. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Jain R; Katic A
Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
[TBL] [Abstract][Full Text] [Related]
25. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
Huang YS; Tsai MH
CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
Pringsheim T; Steeves T
Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
[TBL] [Abstract][Full Text] [Related]
28. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
30. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
Sohn M; Talbert J; Moga DC; Blumenschein K
Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
32. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.
Kollins SH; Jain R; Brams M; Segal S; Findling RL; Wigal SB; Khayrallah M
Pediatrics; 2011 Jun; 127(6):e1406-13. PubMed ID: 21555501
[TBL] [Abstract][Full Text] [Related]
33. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
[TBL] [Abstract][Full Text] [Related]
34. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
[TBL] [Abstract][Full Text] [Related]
35. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Blader JC; Schooler NR; Jensen PS; Pliszka SR; Kafantaris V
Am J Psychiatry; 2009 Dec; 166(12):1392-401. PubMed ID: 19884222
[TBL] [Abstract][Full Text] [Related]
36. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.
Arch Gen Psychiatry; 1999 Dec; 56(12):1088-96. PubMed ID: 10591284
[TBL] [Abstract][Full Text] [Related]
37. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
38. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
39. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Jaworowski S; Benarroch F; Gross-Tsur V
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
[TBL] [Abstract][Full Text] [Related]
40. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
